FAIR VALUE DISCLOSURES (Tables)

6 Months Ended

Jun. 30, 2011

FAIR VALUE DISCLOSURES

Fair value hierarchy for financial assets and liabilities carried at fair value and measured on a recurring basis

			Fair Value Measurements at Reporting Date Using
Description	June 30, 2011		Quoted Prices in  Active Markets for  Identical Assets  (Level 1)		Significant Other  Observable Inputs  (Level 2)		Significant  Unobservable Inputs  (Level 3)
Long term assets Investment in Mesoblast	$	505,800	$	505,800	$	—	$	—
Short term liabilities Letter agreement derivative instrument	$	22,078	$	—	$	—	$	22,078
Long term liabilities Ception contingent consideration	105,630		—		—		105,630
BDC contingent consideration	33,047		—				33,047
Gemin X contingent consideration	98,043		—		—		98,043
Total liabilities	$	258,798	$	—	$	—	$	258,798

Description	December 31, 2010		Quoted Prices in  Active Markets for  Identical Assets  (Level 1)		Significant Other  Observable Inputs  (Level 2)		Significant  Unobservable Inputs  (Level 3)
Current assets
Purchase Option for ChemGenex Equity Securities	$	984	$	—	$	984	$	—
Long term assets
Investment in ChemGenex convertible note securities	9,885		—		—		9,885
Investment in Mesoblast	145,923		145,923		—		—
Total assets	$	156,792	$	145,923	$	984	$	9,885
Long term liabilities
Ception contingent consideration	$	102,942	$	—	$	—	$	102,942
BDC contingent consideration	32,266		—		—		32,266
Total liabilities	$	135,208	$	—	$	—	$	135,208

Reconciliation of the beginning and ending balances for assets and liabilities measured on a recurring basis using unobservable inputs (Level 3)

	Ception  Contingent  Consideration  (Liability)			BDC Contingent  Consideration  (Liability)			ChemGenex  Convertible Note  Securities			GeminX  Contingent  Consideration  (Liability)			Letter  Agreement  Derivative  Instrument
Balance, January 1, 2011	$	(102,942	)	$	(32,266	)	$	9,885		$	—		$	—
Net transfer in to Level 3 (new transactions)	—			—			—			(97,111		)	—
Unrealized gains/(losses) included in earnings	(2,688		)	(781		)	5,115			(932		)	(22,078		)
Conversion of Convertible Notes to Equity (Transfer Out)	—			—			(15,000		)	—			—
Ending Balance, June 30, 2011	$	(105,630	)	$	(33,047	)	$	—		$	(98,043	)	$	(22,078	)

Fair value and carrying value of convertible debt, based on quoted market prices

	Fair Value^		Carrying Value		Face Value
2.0% convertible senior subordinated notes due June 1, 2015	$	1,420,141	$	666,390	$	819,990
2.5% convertible senior subordinated notes due May 1, 2014	615,950		402,989		500,000